secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000950170-24-034701
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics reports FY2023 net loss $62.7M; ENLIGHTEN I Phase 3 topline expected Q2 2024
--------------------------------------------------------------------------------

- Net loss $62.7M in FY2023 ($15.1M Q4); R&D $48.0M, G&A $19.1M; cash $102.8M, runway into Q1 2025.
- Topline results from ENLIGHTEN I Phase 3 trial of LYR-210 in CRS anticipated Q2 2024.
- ENLIGHTEN II enrollment completion expected H2 2024; ENLIGHTEN I 52-week extension results Q4 2024.
- BEACON Phase 2 of LYR-220 met safety endpoint; significant SNOT-22 (−16.8; p=0.007) and 3CS (−1.50; p=0.02) improvement vs sham at week 24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024034701/0000950170-24-034701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024034701/lyra-20240321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer